130 related articles for article (PubMed ID: 35121396)
1. Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.
Chan SK; Lin C; Huang SH; Chau TC; Guo QJ; O'Sullivan B; Lam KO; Chau SC; Chan SY; Tong CC; Vardhanabhuti V; Kwong DLW; So TH; Ng CY; Leung TW; Luk MY; Lee AWM; Choi HCW; Pan JJ; Lee VHF
Oral Oncol; 2022 Mar; 126():105736. PubMed ID: 35121396
[TBL] [Abstract][Full Text] [Related]
2. An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma.
Chan SK; O'Sullivan B; Huang SH; Chau TC; Lam KO; Chan SY; Tong CC; Vardhanabhuti V; Kwong DL; Ng CY; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454830
[TBL] [Abstract][Full Text] [Related]
3. Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma.
Lu TZ; Zeng FJ; Hu YJ; Fang M; Zhong FY; Chen BJ; Zhang H; Guo QJ; Pan JJ; Gong XC; Huang SH; Liao ZH; Xia Y; Li JG
Cancer Med; 2023 Dec; 12(24):22091-22102. PubMed ID: 38073447
[TBL] [Abstract][Full Text] [Related]
4. Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma.
Shen L; Li W; Wang S; Xie G; Zeng Q; Chen C; Shi F; Zhang Y; Wu M; Shu W; Pan C; Xia Y; Wu P
Radiology; 2016 Sep; 280(3):805-14. PubMed ID: 27023116
[TBL] [Abstract][Full Text] [Related]
5. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment.
Zou X; You R; Liu H; He YX; Xie GF; Xie ZH; Li JB; Jiang R; Liu LZ; Li L; Zhang MX; Liu YP; Hua YJ; Guo L; Qian CN; Mai HQ; Chen DP; Luo Y; Shen LF; Hong MH; Chen MY
Eur J Cancer; 2017 May; 77():117-126. PubMed ID: 28391025
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
[TBL] [Abstract][Full Text] [Related]
7. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
[TBL] [Abstract][Full Text] [Related]
8. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
[TBL] [Abstract][Full Text] [Related]
9. Development of a ten-signature classifier using a support vector machine integrated approach to subdivide the M1 stage into M1a and M1b stages of nasopharyngeal carcinoma with synchronous metastases to better predict patients' survival.
Jiang R; You R; Pei XQ; Zou X; Zhang MX; Wang TM; Sun R; Luo DH; Huang PY; Chen QY; Hua YJ; Tang LQ; Guo L; Mo HY; Qian CN; Mai HQ; Hong MH; Cai HM; Chen MY
Oncotarget; 2016 Jan; 7(3):3645-57. PubMed ID: 26636646
[TBL] [Abstract][Full Text] [Related]
10. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.
Yao Y; Sun X; Huang H; Wang Z; Fang X; Chen M; Chen Z; Weng H; Guo C; Hong H; Huang H; Lin T
Radiat Oncol; 2023 Jan; 18(1):15. PubMed ID: 36681832
[TBL] [Abstract][Full Text] [Related]
11. M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma.
Shen L; Dong J; Li S; Wang Y; Dong A; Shu W; Wu M; Pan C; Xia Y; Wu P
Oncologist; 2015 Mar; 20(3):291-8. PubMed ID: 25660157
[TBL] [Abstract][Full Text] [Related]
12. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
[TBL] [Abstract][Full Text] [Related]
13. Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: A subset with better overall survival.
Tian YH; Zou WH; Xiao WW; Zeng L; Yuan X; Bai L; Lu T; Tian Y; Han F
Head Neck; 2016 Aug; 38(8):1152-7. PubMed ID: 27220062
[TBL] [Abstract][Full Text] [Related]
14. Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas.
Lin M; Yang Q; You R; Zou X; Duan CY; Liu YP; Huang PY; Xie YL; Wang ZQ; Liu T; Chen SY; Hua YJ; Chen MY
Oral Oncol; 2021 Apr; 115():105200. PubMed ID: 33610003
[TBL] [Abstract][Full Text] [Related]
15. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature.
Pan CC; Lu J; Yu JR; Chen P; Li W; Huang ZL; Zhao M; Huang ZM; Xia YF; Wu YH; Wu PH
Exp Ther Med; 2012 Aug; 4(2):334-338. PubMed ID: 23139721
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.
O'Sullivan B; Huang SH; Su J; Garden AS; Sturgis EM; Dahlstrom K; Lee N; Riaz N; Pei X; Koyfman SA; Adelstein D; Burkey BB; Friborg J; Kristensen CA; Gothelf AB; Hoebers F; Kremer B; Speel EJ; Bowles DW; Raben D; Karam SD; Yu E; Xu W
Lancet Oncol; 2016 Apr; 17(4):440-451. PubMed ID: 26936027
[TBL] [Abstract][Full Text] [Related]
18. A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers.
Lai C; Zhang C; Lv H; Huang H; Ke X; Zhou C; Chen H; Chen S; Zhou L
Cancer Med; 2021 Jun; 10(11):3511-3523. PubMed ID: 33973727
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis.
Lin C; Lin S; Zhu L; Lin S; Pan J; Xu Y
BMC Cancer; 2022 Jan; 22(1):35. PubMed ID: 34983459
[TBL] [Abstract][Full Text] [Related]
20. A nonendemic analysis of the patterns and prognosis of de novo metastatic nasopharyngeal carcinomas in older patients aged ≥ 65 years.
Liu B; Zhang M; Cao Y; Wang Z; Wang X
Sci Rep; 2022 May; 12(1):8321. PubMed ID: 35585123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
